ライフサイエンスコーパス: PPI

1 31/146] with PPI and 91.5% [613/670] without PPI).

2 phosphate + Pi [Formula: see text] acetate + PPi).

3 inorganic phosphate (Pi) and pyrophosphate (PPi).

4 o have hypertension and receive statins than PPI-.

5 rett's esophagus should consider a long-term PPI.

6 or the discovery of novel inhibitors of this PPI.

7 n the copper complex of PDI-HIS receptor and PPi.

8 and symptomatic GERD should take a long-term PPI.

9 nerating a unique RNA output signal for each PPI.

10 vestigate whether Galphai-GIV is a druggable PPI.

11 ion of p38 and its activation of MYC through PPI.

12 eactions to alternative structurally similar PPI.

13 ol to investigate the exquisite mechanism of PPIs.

14 cial to obtain the tertiary structure of the PPIs.

15 ate at damage sites with local enrichment of PPIs.

16 ol for large-scale investigations of dynamic PPIs.

17 and uncover inhibitor-dependent competitive PPIs.

18 into the molecular mechanisms of disordered PPIs.

19 r respective species data, we found only 429 PPIs ( 1% of the available data) conserved in two or mor

20 acteristic of the expected biradical sigma(1)ppi(1) spin configuration according to a combination of

21 ollment, PPI+ group lost more CD4 cells than PPI- (-18 vs. 54 cells/mm3, P = .03).

22 ich is rapidly converted into pyrophosphate (PPi), a major calcification inhibitor.

23 ve a profound defect in prepulse inhibition (PPI), a measure of sensorimotor gating commonly deficien

24 Both >/=2 years of PPIs (adjusted odds ratio, 2.49; 95% confidence interval

25 ss-hypersensitivity or tolerability to other PPI after their hypersensitivity episodes.

26 eal thickness, pachymetry progression index (PPI), Ambrosio relational thickness (ART), posterior ele

27 amined whether reduced levels of circulating PPi, an antimineralization factor, is the sole mechanism

28 ate binary (1 x 1) and ternary (1 x 2) Bcl-2 PPI analyses by imaging fluorescent protein translation

29 Psychophysiological interaction (PPI) analyses showed that coupling between the hippocamp

30 sitivity, SPARK has the potential to advance PPI analysis and discovery.

31 Psycho-physiological interaction (PPI) analysis revealed that dot periodicity modulated fu

32 RBV did not affect SVR (89.7% [131/146] with PPI and 91.5% [613/670] without PPI).

33 Complete collection of repeated PPI and H2B dispensations at pharmacies in Sweden allowe

34 Consistent with both their PPI and learning defects, cortical pyramidal neurons fro

35 the pro-attentional drug, d-amphetamine, on PPI and neurocognition in antipsychotic-medicated schizo

36 Plasma levels of PPi and the degree of ectopic mineralization were determ

37 MII-pH measurements on-PPI and with healthy controls will be useful in the furt

38 (3.0%) received a prior >/=2-year supply of PPIs and 1063 (1.4%) received H2RAs (without PPI use).

39 (0.9%) received a prior >/=2-year supply of PPIs and 2247 (0.6%) H2RAs.

40 The adjusted OR for current use of PPIs and development of listeriosis was 2.81 (95% confid

41 ethods have difficulty in solving disordered PPIs and existing protein-protein and protein-peptide do

42 y significant associations (signals) between PPIs and fractures.

43 ore than 5 million new users of prescription PPIs and H2RAs.

44 Data on use of PPIs and other drugs and hospitalization diagnoses over

45 We calculated the association between use of PPIs and related drugs within 30 days (current use) and

46 oaches explored for the modulation of 14-3-3 PPIs and review the examples resulting from these effort

47 d association between cumulative exposure to PPIs and risk of CKD progression.

48 tatus was assessed with prepulse inhibition (PPI) and auditory brainstem responses (ABRs).

49 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) suppr

50 e recruited 77 HIV-infected participants (37 PPI+ and 40 PPI-) and 20 HIV-uninfected volunteers.

51 77 HIV-infected participants (37 PPI+ and 40 PPI-) and 20 HIV-uninfected volunteers.

52 d the practical utility for the detection of PPi anions by "off-on" response rapidly in a label free

53 BACKGROUND & AIMS: Proton pump inhibitors (PPI) are among the top 10 most prescribed medications wo

54 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly used medications.

55 Protein-protein interactions (PPIs) are crucial in many biological processes.

56 Phosphoinositide lipids (PPIs) are enriched in the nucleus and are accumulated at

57 Phosphorylated phosphoinositide lipids (PPIs) are low-abundance signaling molecules that control

58 Proton pump inhibitors (PPIs) are widely used to treat gastric acid-related diso

59 This work establishes the Galphai-GIV PPI as a druggable target and sets the conceptual and te

60 es', where signals were detected for overall PPIs as well as for each of 5 generic ingredients (insuf

61 teins, depending on available information on PPIs, as we demonstrate in several examples.

62 Current technologies, which assay one PPI at a time, are too low throughput to make it practic

63 PPiSeq detects PPIs at a rate that is on par with current assays and, i

64 ne loading or aminopolymer architecture, the PPI-based sorbents are found to be more efficient for CO

65 ans and patients should not avoid starting a PPI because of concerns related to MI risk.

66 nd specific to quantify both strong and weak PPIs between influenza virus polymerase subunits.

67 nhibitor of the protein-protein interaction (PPI) between the transcription factor Nrf2 and its negat

68 PPI-binding domains rapidly (< 1 s) accumulate at damage

69 reveal hPolbeta in an open conformation with PPi bound in the active site, thereby strongly suggestin

70 hich models the conformation of a disordered PPI by considering the biophysical binding mechanism of

71 ction of >1,000 compounds on the Galphai-GIV PPI by in silico ligand screening and separately by a ch

72 rolyl isomerase D (cyclophilin D, encoded by Ppid) by administration of L-arginine (also in rats), ca

73 In fact, PPI can reveal how inter-regional amygdala communication

74 Protein-protein interactions (PPIs) can offer compelling evidence for protein function

75 We analyzed the causative PPI, clinical manifestations, organ involvement, treatme

76 Users of PPIs, compared with users of H2Bs, had an increased risk

77 Thirteen patients allergic to one kind of PPI could tolerate other structurally different PPI with

78 ociated with the growing DNA strands and Mg2 PPi crystals during the rolling circle process, ultimate

79 s and global network aligners on large scale PPI data and observe that three methods, HUBALIGN, L-GRA

80 Although experimental PPI data have increased significantly over recent years,

81 Finally, PPI deficits were exacerbated by allopregnanolone (10 mg

82 After placebo, patients exhibited PPI deficits with 60 ms prepulse intervals; these defici

83 deficiency can be prevented by compensating PPi deficits, even partially.

84 -100 mg/kg, IP) dose-dependently ameliorated PPI deficits, hyperactivity, and risk-taking behaviors,

85 r environment via fluorescence "turn-on" for PPi detection.

86 percentage of proximal esophageal reflux off-PPI did not change significantly after one year, but the

87 suggests that nucleotide binding stimulates PPi dissociation and occurs before polymerase translocat

88 lly reevaluated so that the lowest effective PPI dose can be prescribed to manage the condition.

89 PPI dose escalation and continued chronic therapy in tho

90 e high background and lose information about PPI dynamics.

91 All categories of PPIs, except rabeprazole, were associated with an increa

92 Initiation of PPI therapy and cumulative PPI exposure is associate with increased risk of CKD pro

93 me-dependent risk associated with cumulative PPI exposure.

94 ith long-term use of proton pump inhibitors (PPIs), focusing on long-term use of PPIs for three commo

95 ophagitis or peptic stricture) should take a PPI for short-term healing, maintenance of healing, and

96 ibitors (PPIs), focusing on long-term use of PPIs for three common indications: gastroesophageal refl

97 Best Practice Advice 10: Specific PPI formulations should not be selected based on potenti

98 Proton pump inhibitors (PPIs), frequently prescribed to patients with cirrhosis,

99 In the year prior to enrollment, PPI+ group lost more CD4 cells than PPI- (-18 vs. 54 cel

100 lex network of protein-protein interactions (PPIs) has now been widely recognized as an attractive me

101 en though this is a challenging endeavor and PPIs have long been regarded as "undruggable" targets, t

102 PPIs have the potential to induce life-threatening DHR.

103 BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with acute kidney injury and r

104 Proton pump inhibitors (PPIs) have been known to induce type I hypersensitivity

105 sues associated with proton pump inhibitors (PPIs) have recently attracted widespread media and lay a

106 ue platform for the fluorogenic detection of PPi having a very low limit of detection (LOD) of 0.60x1

107 e development of all-cis polyproline type I (PPI) helices, as tools for modulating biological functio

108 be solved for any linear peptoid, revealed a PPI helix of great regularity despite the presence of on

109 re of an Ns1tbe pentamer revealed an all-cis PPI helix, and the CD curves of the Ns1tbe oligomers als

110 PPI hubs reveal new regulatory mechanisms for cancer gen

111 r-related bleeding from NSAIDs should take a PPI if they continue to take NSAIDs.

112 noSPD for a range of nuclear and cytoplasmic PPIs implicated in human deafness, in addition to dissec

113 ep towards the molecular characterisation of PPIs implies the charting of their interfaces, that is,

114 Amphetamine acutely 'normalized' PPI in antipsychotic-medicated schizophrenia patients; n

115 s, and investigated the T-cell reactivity to PPI in PPI-related DHR patients.

116 GO proved very valuable for the detection of PPi in unprecedented sensitivity over other competing io

117 feasibility to identify a PPI inhibitor, 26 PPIs in DDR pathways (BER, MMR, NER, NHEJ, HR, TLS, and

118 Here, we investigate roles of nuclear PPIs in DNA damage response by sequestering specific PPI

119 SPARK was used to detect 12 different PPIs in mammalian cells, with 5 min temporal resolution

120 nsurance beneficiaries, we found that use of PPIs in patients with cirrhosis increases the risk for H

121 e use of small molecule poly(propylenimine) (PPI) in linear and dendritic architectures supported in

122 te probe for the detection of pyrophosphate (PPi) in physiological conditions and in in vitro live me

123 g development commonly involves inhibiting a PPI, in this study, we show that stabilizing PPI may als

124 ontrol pericellular concentrations of Pi and PPi include tissue-nonspecific alkaline phosphatase (TNA

125 s with limited to no experimentally observed PPI, including Bacillus subtilis and Salmonella enterica

126 lans, we found no evidence that prescription PPIs increase risk of MI compared with prescription H2RA

127 Here Llorente et al. show that PPIs induce bacterial overgrowth of enterococci, which,

128 In the absence of LRAP, PPi inhibition was reversed by the presence of etched en

129 le and biochemical feasibility to identify a PPI inhibitor, 26 PPIs in DDR pathways (BER, MMR, NER, N

130 highlights the unique features of Keap1-Nrf2 PPI inhibitors as inducers of mitophagy and their potent

131 Structurally distinct Keap1-Nrf2 PPI inhibitors promote mitochondrial turnover, while cov

132 lytica ACK (EhACK) which uses pyrophosphate (PPi)/inorganic phosphate (Pi) (acetyl phosphate + Pi [Fo

133 in the Abcc6(-/-) rats leading to a lowered PPi/inorganic phosphate plasma ratio.

134 proof of a supramolecular ligand targeting a PPI interface and stabilizing the binding of an intrinsi

135 affinity pulldown, a gold-standard in vitro PPI interrogation technique, to perform nanoscale pulldo

136 Moreover, PPI is found to be more resistant to oxidative degradati

137 In patients when PPI is necessary for treatment, switching to structurall

138 In the meantime, cautious use of PPIs is advised.

139 We hypothesized that long-term use of PPIs is associated with greater microbial translocation

140 Targeting protein-protein interaction (PPI) is rapidly becoming an attractive alternative for d

141 ng of the molecular mechanisms of disordered PPIs, it is crucial to obtain the tertiary structure of

142 he commonly prescribed and cheaply available PPI lansoprazole was associated with reduced incidence o

143 Plasma inorganic pyrophosphate (PPi) level was reduced (<30%) in the Abcc6(-/-) rats lea

144 The sensitivity of cementum to reduced PPi levels in both human and mouse teeth establishes thi

145 the relative contribution of these organs to PPi levels in circulation.

146 /-) rats were significantly reduced, but the PPi levels in the liver perfusates of wild-type rats wer

147 PPi levels in the perfusates both in the liver and kidne

148 n ENPP1 in Enpp1(asj) mice normalized plasma PPi levels to that of wild-type mice and, consequently,

149 e of hepatic ABCC6 in contributing to plasma PPi levels, identifying liver as a target of molecular c

150 , resulting in only a 27% increase in plasma PPi levels, led to a major reduction in acute and chroni

151 were still evident despite increased plasma PPi levels.

152 ntly reduced plasma inorganic pyrophosphate (PPi) levels underlie PXE.

153 ess induced by gemcitabine exposure based on PPIs map.

154 innest pachymetry, ARTmax, BDE, D index, and PPI max were 0.82, 0.61, 0.88, 0.67, and 0.64, respectiv

155 (BDE), pachymetric progression index maximum(PPI max), and multimetric D were significantly higher co

156 PPI, in this study, we show that stabilizing PPI may also be therapeutically beneficial.

157 PPIs may have unwanted side effects in vulnerable popula

158 studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis.

159 Each PPI-mediated RNAPN-RNAPC assembly transcribes from a sep

160 Together, these findings reveal that nuclear PPI metabolism mediates an early damage response through

161 PPI modulation requires novel approaches and the integra

162 increasing number of successful examples of PPI modulators, resulting in growing interest in this fi

163 for the rapid discovery of new alpha-helical PPI modulators.

164 We identified new users of PPIs (n = 105,305) and new users of H2 blockers (H2B; n

165 bled 51 fold enrichment of PPI-positive over PPI-negative cells.

166 Next, we perform a 1 x 4 PPI network analysis by direct measurement of four uniqu

167 nknown meiotic proteins, and we show how the PPI network can be used to prioritise candidates for ana

168 we report the generation of a cancer-focused PPI network, termed OncoPPi, and identification of >260

169 form a coherent protein-protein interaction (PPI) network containing known and candidate meiotic prot

170 , we reported a protein-protein interaction (PPI) network of cancer-associated genes, termed OncoPPi,

171 f genes given a protein-protein interaction (PPI) network, we simulated microarray gene expression da

172 s from a single protein-protein interaction (PPI) network.

173 proposed approach can tolerate edge loss in PPI networks and even discover sparse protein complexes

174 haviour of network aligners and observe that PPI networks are almost entirely aligned with a handful

175 Hence, PPI networks are already well investigated by current al

176 Mapping protein structures to these PPI networks not only provides structural details of eac

177 reased significantly over recent years, most PPI networks still have many false positive interactions

178 Traditional Protein-Protein Interaction (PPI) networks, which use a node and edge representation,

179 n 30 cumulative defined daily doses (cDDDs); PPI nonuse was defined as 30 cDDDs or fewer.

180 than 365 cDDDs, respectively, compared with PPI nonusers.

181 and identification of >260 cancer-associated PPIs not in other large-scale interactomes.

182 Forty-three and 49% of the patients used PPIs (NS).

183 eveloped an innovative method to investigate PPIs of multisubunit complexes effectively and to identi

184 Prepulse inhibition (PPI) of startle is being explored both as an indicator o

185 lly catalogued protein-protein interactions (PPIs) of a cell in a single environment.

186 by focusing on protein-protein interactions (PPIs) of the key DDR components.

187 Protein-protein interactions (PPIs) of these subunits play pivotal roles in assembling

188 first time analyzed the effect of decreased PPi on dental development in individuals with generalize

189 to be significantly lower in patients taking PPI (P = .0052).

190 mozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months.

191 Tackling PPIs, particularly by stabilizing clinically favored con

192 the Ns1tbe oligomers also resemble those of PPI peptide helices.

193 The PPI phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2)

194 ronger for higher daily doses (>1.5 vs <0.75 PPI pills/d; P value interaction = .004) and decreased a

195 e known role mineralization inhibitors, like PPi, play in the regulation of mineralized tissue format

196 th FACS, SPARK enabled 51 fold enrichment of PPI-positive over PPI-negative cells.

197 Proton pump inhibitors (PPIs) predispose to bacterial overgrowth in the gut.

198 We investigated whether PPI predisposes patients with cirrhosis to HE using a la

199 Thus early cancer detection via PPi recognition in physiological conditions and in live

200 n bind simultaneously to a flexible peptidic PPI recognition motif and to a well-structured adapter p

201 hronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secretion and modulate gut mic

202 udies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population.

203 h co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70-90%, u

204 99, 177 patients with proton pump inhibitor (PPI)-refractory GERD were randomized to CNF or LNF.

205 Among individuals who did not use PPIs regularly, duration of H2RA use was associated with

206 Protein-protein interactions (PPIs) regulate assembly of macromolecular complexes, yet

207 omeprazole was the most commonly involved in PPI-related DHR (51%).

208 We retrospectively analyzed patients with PPI-related DHR from multiple medical centers in Taiwan

209 investigated the T-cell reactivity to PPI in PPI-related DHR patients.

210 We conducted a study of a large series of PPI-related DHR, followed up their tolerability to alter

211 There were 69 cases of PPI-related DHR, including SJS/TEN (n=27) and DRESS (n=1

212 hPolbeta) and provide a structural basis for PPi release.

213 everse conformational changes occur prior to PPi release.

214 While acoustic PPI remained intact and ABR thresholds recovered, the AB

215 re predicted to have up to 18,000 and 31,000 PPIs, respectively.

216 led to much of the current controversy about PPI safety.

217 Both PPI scoring and the bulk of strain construction can be p

218 involving ATM and DNA-PKcs are unaffected by PPI sequestration.

219 Patients with a proven indication for a PPI should continue to receive it in the lowest effectiv

220 est Practice Advice 6: The dose of long-term PPIs should be periodically reevaluated so that the lowe

221 Patients who cannot reduce PPIs should consider ambulatory esophageal pH/impedance

222 uncomplicated GERD who respond to short-term PPIs should subsequently attempt to stop or reduce them.

223 PPI strategies, such as selecting the target PPI site on the basis of its functionality, are discusse

224 ection of the enamel rods, were exposed to a PPi-stabilized supersaturated calcium phosphate (CaP) so

225 General requirements for PPI strategies, such as selecting the target PPI site on

226 PPI+ subjects were older and more likely to have hyperte

227 Our work indicates that PPi substitution represents a promising strategy to trea

228 hypersensitivity reactions (DHR) induced by PPI, such as Stevens-Johnson syndrome (SJS), toxic epide

229 previously reported as being associated with PPIs, such as 'rib fractures', where signals were detect

230 e bound to the active site in the absence of PPi, suggests that nucleotide binding stimulates PPi dis

231 We observed a relationship between dose of PPI taken and HE risk.

232 many of the proposed adverse consequences of PPI therapy and apply established criteria for the deter

233 Initiation of PPI therapy and cumulative PPI exposure is associate wit

234 Furthermore, some patients may have had PPI therapy discontinued abruptly or inappropriately due

235 The benefits of PPI therapy for appropriate indications need to be consi

236 requently asked about the appropriateness of PPI therapy for specific patients.

237 h an empiric trial of proton pump inhibitor (PPI) therapy and complementary lifestyle measures, for p

238 ation of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related Quality of Life scores

239 iew of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy

240 Disordered protein-protein interactions (PPIs), those involving a folded protein and an intrinsic

241 fting the light window, we could reconstruct PPI time-courses.

242 We also found that daily injection of PPi to Abcc6(-/-) mice over several months prevented the

243 ed transcription factor (TF) requires both a PPI to deliver a protease proximal to its cleavage pepti

244 s amplify fluorescence intensities and allow PPIs to be interrogated using standard epifluorescence m

245 nce monitoring before committing to lifelong PPIs to help distinguish GERD from a functional syndrome

246 combines the use of inorganic pyrophosphate (PPi) to control the onset and rate of enamel regeneratio

247 alyze the hydrolysis of inorganic phosphate (PPi) to inorganic phosphate Pi, driving biosynthetic rea

248 rategy that exploits selective alpha-helical PPIs, transferring these characteristics to small molecu

249 PPI treatment significantly reduces the need for phlebot

250 s thought that the release of pyrophosphate (PPi) triggers reverse conformational changes in a polyme

251 PPI usage up to 90 days before the index date remained s

252 PPI use also associated with development of end-stage re

253 ociation between risk of incident stroke and PPI use among participants.

254 However, data are lacking on long-term PPI use and cognitive function.

255 not observe a convincing association between PPI use and cognitive function.

256 d not find a significant association between PPI use and ischemic stroke, after accounting for indica

257 We therefore examined associations between PPI use and performance in tests of cognitive function.

258 analyses to estimate the association between PPI use and the occurrence of HE.

259 Based on data mining from AERS-DM, PPI use appears to be associated with an increased risk

260 rrence of HE, 38% (n = 445) had a history of PPI use before HE occurrence.

261 re providers to carefully consider prolonged PPI use by patients with cirrhosis.

262 Our data do not support the suggestion that PPI use increases dementia risk.

263 The estimated NNT for routine PPI use to prevent one disabling or fatal upper gastroin

264 trointestinal, the estimated NNT for routine PPI use to prevent such bleeds is low, and co-prescripti

265 ent for established risk factors for stroke, PPI use was associated with a significant increase in ri

266 PPI use was defined as more than 30 cumulative defined d

267 Regular PPI use was not associated with increased risk of stroke

268 PPI use with LDV/SOF +/- RBV did not affect SVR (89.7% [

269 African American race or PPI use with LDV/SOF +/- RBV was not associated with low

270 drugs (mainly aspirin based, without routine PPI use) after the event in the Oxford Vascular Study fr

271 PPIs and 1063 (1.4%) received H2RAs (without PPI use).

272 reflux symptoms, dysphagia, general health, PPI use, and need for surgical reintervention at 17 year

273 er we adjusted for potential indications for PPI use, including history of peptic ulcer disease, gast

274 Because our primary hypothesis related to PPI use, our findings for H2RAs should be interpreted wi

275 elated to chronic conditions associated with PPI use.

276 stroke, after accounting for indications for PPI use.

277 associations between proton pump inhibitor (PPI) use and dementia.

278 Of PPI users reporting fractures, the mean age was 65.3 yea

279 Best Practice Advice 8: Long-term PPI users should not routinely raise their intake of cal

280 Best Practice Advice 9: Long-term PPI users should not routinely screen or monitor bone mi

281 Best Practice Advice 7: Long-term PPI users should not routinely use probiotics to prevent

282 risk of acute myocardial infarction (MI) in PPI users vs non-users.

283 Among PPI users, the associations were stronger for higher dai

284 eriaceae (ESBL-E), compared with 2.9% of non-PPI users.

285 The intracellular detection of PPi using PCG also carried out in B16F10 cells where >10

286 re involved in protein-protein interactions (PPIs) very often display a high degree of intrinsic diso

287 nces in MI risk between patients who started PPIs vs H2RAs for the first 12 months, either in the com

288 patients who started a new prescription for PPIs vs H2RAs.

289 The cross-reactivity to structurally similar PPI was also observed in LAT assay.

290 The magnitude of amphetamine-enhanced PPI was greater in patients than in HS (p<0.032), and wa

291 s substrates, and enzymatic activity with Pi/PPi was negatively impacted.

292 In HIV, long-term use of PPIs was associated with increased microbial translocati

293 A total of 25 reproducible PPIs were found for a selected set of 10 Giles proteins,

294 5% of patients using proton pump inhibitors (PPIs) were rectal carriers of extended-spectrum beta-lac

295 with current methods, quantitatively scores PPIs with enough accuracy and sensitivity to detect chan

296 On a dataset of 22 disordered PPIs with IDPs up to 69 amino acids, successful predicti

297 Targeting PPIs with small molecules can be challenging owing to la

298 DNA damage response by sequestering specific PPIs with the expression of nuclear-targeted PH domains,

299 ties to reveal protein-protein interactions (PPIs) with functional and therapeutic significance.

300 could tolerate other structurally different PPI without cross-hypersensitivity reactions, whereas th